newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half